Skip to main content

Table 1 Basic characteristics of the enrolled patients (n = 34)

From: Molecular imaging of HER2 expression in breast cancer patients using a novel peptide-based tracer 99mTc-HP-Ark2: a pilot study

Patient No

Age

Pathologic diagnosis

IHC

FISH

99mTc-HP-Ark2 SPECT/CT

18F-FDG PET/CT

Tumor

Breast tissue

T/B ratio

Tumor

Breast tissue

T/B ratio

Countsavg

Countsmax

Countsavg

Countsmax

SUVmean

SUVmax

SUVmean

SUVmax

1

39

ILC

2 + 

−

141

154

86

95

1.64

6.1

7.6

0.39

0.56

15.64

2

63

IDC

1 + 

 

91

104

85

104

1.07

0.8

1.1

0.5

0.6

1.6

3

56

IDC

0

 

55

64

40

54

1.38

2.7

3.5

0.6

0.8

4.5

4

52

MeC

3 + 

 

143

171

77

87

1.86

5.3

8.1

0.3

0.8

17.67

5

60

IDC

2 + 

 + 

186

209

102

123

1.82

5.4

8.4

0.7

0.9

7.71

6

33

IDC

1 + 

 

65

85

65

87

1

5.8

7.8

0.5

0.8

11.6

7

41

IDC

2 + 

 + 

227

245

93

107

2.44

8.2

11.6

1.1

1.6

7.45

8

38

MuC

1 + 

 

71

91

87

115

0.82

1.6

2.3

0.9

1.2

1.78

9

42

IDC

1 + 

 

80

106

60

78

1.33

7.9

9.1

1.2

1.7

6.58

10

32

IDC

3 + 

 

131

157

82

122

1.6

13.5

19.6

1.5

1.9

9

11

45

IDC

1 + 

 

112

133

88

99

1.27

3.2

4.5

0.9

1.2

3.56

IDC

1 + 

 

121

128

88

99

1.38

2.5

4.3

0.9

1.2

2.78

12

38

IC

1 + 

 

187

210

177

221

1.06

2.7

3.7

1.8

1.2

1.5

13

53

IDC

1 + 

 

170

200

128

142

1.33

3.3

4.1

0.3

0.4

11

14

58

IDC

2 + 

 

132

154

55

61

2.4

7.6

9.1

0.5

0.7

15.2

15

50

IDC

2 + 

+ 

40

50

24

32

1.67

3.7

5.5

1.8

2.3

2.06

16

54

IC

2 + 

−

109

116

82

87

1.33

2.6

3.4

0.6

0.8

4.33

17

36

ILC

1 + 

 

87

115

123

170

0.71

1.5

1.8

1.5

1.9

1

18

49

IDC

2 + 

−

217

219

191

211

1.14

3.2

4.3

1.6

2.3

2

19

48

IDC

3 + 

 

170

202

105

123

1.62

5.3

7.8

1.5

2

3.53

20

60

IDC

3 + 

 

243

294

83

93

2.93

6.2

8.5

0.5

0.9

12.4

21

45

IDC

2 + 

+ 

264

293

71

103

3.72

6

9.5

0.3

0.6

20

22

61

IDC

2 + 

−

289

310

60

65

4.82

7.7

10.2

0.8

0.9

9.63

23

38

IDC

1 + 

 

223

256

137

141

1.63

7.8

10.5

1.5

1.8

5.2

24

53

IDC

3 + 

 

259

292

84

100

3.08

3.5

5

0.6

0.8

5.83

25

38

IDC

1 + 

 

135

153

104

116

1.3

1.5

2.2

1.1

1.6

1.36

IDC

1 + 

 

128

141

104

116

1.23

1.6

2.1

1.1

1.6

1.45

26

57

IDC

3 + 

 

359

400

85

95

4.22

8.8

12.9

1.3

1.5

6.77

27

54

IDC

3 + 

 

220

237

107

122

2.06

5.2

6.8

1.1

1.3

4.73

28

42

IDC

1 + 

 

161

172

193

206

0.83

1.6

1.8

1.1

1.2

1.45

29

58

IDC

3 + 

 

197

206

65

72

3.03

6.6

10

1.1

1.2

6

30

48

MuC

0

 

130

137

168

210

0.77

1.1

1.9

1.1

1.4

1

31

67

IDC

0

 

133

165

80

96

1.66

2.7

3.7

0.5

0.5

5.4

32

34

IDC

1 + 

 

120

135

125

135

0.96

2.6

3

0.8

1

3.25

33

60

IDC

2 + 

−

387

435

86

124

4.5

7.3

8.3

1.5

1.9

4.87

34

55

IDC

2 + 

−

141

156

94

106

1.5

6.6

9.6

1.3

1.6

5.08

  1. IHC immunohistochemistry, FISH fluorescence in situ hybridization, T/B ratio of tumor-to-background (breast), Countsavg average counts, Countsmax maximum counts, SUVmean mean standardized uptake value, SUVmax maximum standardized uptake value, ILC invasive lobular carcinoma, IDC invasive ductal carcinoma, MeC medullary carcinoma; IC: intraductal carcinoma; MuC: mucinous carcinoma
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us